← back to search

Richard S.P. Huang

TGS (United Kingdom) · GB
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Sarcoma Diagnosis and Treatment, and Cancer, Hypoxia, and Metabolism.
h-index
30
citations
3,078
works
311
NIH funding
primary concept
email

Recent publications

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
Journal for ImmunoTherapy of Cancer 2025cited by 36position: middledoi
Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC).
Journal of Clinical Oncology 2025cited by 2position: middledoi
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Breast Cancer Research and Treatment 2024cited by 35position: middledoi
Use of UV mutational signatures to distinguish between cutaneous and pulmonary primary squamous cell carcinoma
Journal of Cutaneous Pathology 2024cited by 3position: middledoi
Novel <i>SOX10</i> indel mutations drive schwannomas through impaired transactivation of myelination gene programs
Neuro-Oncology 2023cited by 29position: middledoi
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma
Lung Cancer 2023cited by 16position: middledoi
Immunotherapy in the Treatment of Localized Genitourinary Cancers
JAMA Oncology 2023cited by 13position: middledoi
The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer
Clinical Genitourinary Cancer 2023cited by 6position: middledoi
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
JAMA Network Open 2022cited by 87position: middledoi
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
Journal for ImmunoTherapy of Cancer 2021cited by 51position: middledoi
Performance of the Verigene® enteric pathogens test, Biofire FilmArray™ gastrointestinal panel and Luminex xTAG® gastrointestinal pathogen panel for detection of common enteric pathogens
Diagnostic Microbiology and Infectious Disease 2016cited by 113position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jeffrey S. Ross · SUNY Upstate Medical University6 papers (2021–2025)Alexa B. Schrock · GlobalFoundries (United States)4 papers (2022–2025)Ryon P. Graf · Boston University4 papers (2022–2025)Geoffrey R. Oxnard · Boston Medical Center3 papers (2022–2025) · 3 papers (2022–2023)Gerald Li · Ruijin Hospital2 papers (2024–2025) · 2 papers (2023–2025)Brian M. Alexander · Fox Chase Cancer Center2 papers (2021–2022)James Haberberger · Seattle University2 papers (2021–2022) · 2 papers (2024–2025)Neeraj Agarwal · University of Utah2 papers (2022–2025)Hanna Tukachinsky · Foundation Medicine (United States)2 papers (2023–2024)Mia Levy · Rush University Medical Center2 papers (2022–2024)David R. Gandara · Comprehensive Blood & Cancer Center1 papers (2025–2025)Ümit Tapan · Boston University1 papers (2023–2023)Susan F. Slovin · Weill Cornell Medicine1 papers (2023–2023)Bishoy M. Faltas · Cornell University1 papers (2023–2023)Sumanta K. Pal · City of Hope1 papers (2023–2023) · 1 papers (2025–2025) · 1 papers (2024–2024)